Lymphoseek
Total Payments
$1.8M
Transactions
828
Doctors
530
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $272,717 | 95 | 51 |
| 2019 | $186,026 | 239 | 173 |
| 2018 | $990,161 | 374 | 244 |
| 2017 | $366,781 | 120 | 99 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 64 | 71.4% |
| Consulting Fee | $442,319 | 122 | 24.4% |
| Travel and Lodging | $25,768 | 37 | 1.4% |
| Space rental or facility fees (teaching hospital only) | $20,443 | 22 | 1.1% |
| Food and Beverage | $19,673 | 570 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,627 | 10 | 0.6% |
| Education | $48.87 | 3 | 0.0% |
Payments by Type
Research
$1.3M
64 transactions
General
$519,879
764 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous Injection and Skeletal Joint Imaging with SPECT in Subjects with Active Rheumatoid Arthritis and Healthy Controls | Navidea Biopharmaceuticals, Inc. | $233,409 | 0 |
| An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous Injection and a Comparison to Subcutaneous Injection in Human Immunodeficiency Virus Subjects Diagnosed with Kaposi Sarcoma | Navidea Biopharmaceuticals, Inc. | $192,683 | 0 |
| Randomized phase II/III trial of sentinel lymph node biopsy | Cardinal Health 414 LLC | $189,067 | 0 |
| An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid by Planar and SPECT CT Imaging in Subjects with Nonalcoholic Steatohepatitis and Healthy Controls | Navidea Biopharmaceuticals, Inc. | $131,392 | 0 |
| NAV3-18 | Cardinal Health 414, LLC | $103,936 | 0 |
| A randomized controlled double-blinded study comparing the intraoperative injection | Cardinal Health 414, LLC | $21,580 | 0 |
| NAV3-19 | Cardinal Health 414, LLC | $15,708 | 0 |
| A randomized controlled double-blinded study comparing the intraoperative injection of lymphatic mapping agents | Cardinal Health 414 LLC | $12,626 | 0 |
| Retrospective Comparison Evaluating Sulfur Colloid versus Lymphoseek in a Clinical Setting | Cardinal Health 414 LLC | $8,559 | 0 |
| NAV3-18 | Cardinal Health 414 LLC | $5,800 | 0 |
| A Prospective Randomized Parallel Group Double-Blinded Clinical Trial | Cardinal Health 414, LLC | $3,449 | 1 |
| A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection | Navidea Biopharmaceuticals, Inc. | $3,323 | 0 |
Top Doctors Receiving Payments for Lymphoseek
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Wilmington, DE | $1.3M | 83 |
| , M.D | Emergency Medicine | Westerville, OH | $214,812 | 30 |
| , M.D | Surgery | Indianopolis, IN | $51,313 | 36 |
| Adam Berger | — | Philadelphia, PA | $30,626 | 24 |
| , MD | Surgical Oncology | Tampa, FL | $23,940 | 19 |
| , MD,PHD | Otolaryngology | Houston, TX | $22,050 | 14 |
| , M.D | Diagnostic Radiology | Philadelphia, PA | $21,420 | 17 |
| , MD | Surgery | Portland, OR | $11,131 | 4 |
| , MD | Otolaryngology | Cleveland, OH | $11,109 | 5 |
| , M.D | Surgical Oncology | Houston, TX | $11,095 | 5 |
| , M.D | Surgery | New York, NY | $10,881 | 5 |
| , M.D | Surgical Oncology | Stanford, CA | $10,289 | 5 |
| , M.D | Surgery | Santa Monica, CA | $10,240 | 5 |
| , M.D | Surgical Oncology | Durham, NC | $9,010 | 4 |
| , M.D | Surgery | New York, NY | $8,998 | 4 |
| , M.D | Surgery | Brooksville, FL | $7,196 | 4 |
| , M.D | Surgical Oncology | Stamford, CT | $4,900 | 1 |
| , MD | Surgery | Scottsdale, AZ | $4,900 | 1 |
| , M.D | Surgical Oncology | Tarzana, CA | $4,900 | 1 |
| , M.D | Surgical Oncology | Greenvale, NY | $4,900 | 1 |
| , MD | Surgery | Albuquerque, NM | $4,900 | 1 |
| , DO | Surgery | Troy, MI | $4,900 | 1 |
| , MD | Surgical Oncology | Southampton, PA | $4,900 | 1 |
| , MD | Nuclear Medicine | Dayton, OH | $3,500 | 4 |
| , MD | Surgical Oncology | San Francisco, CA | $3,150 | 1 |
Ad
Manufacturing Companies
- Navidea Biopharmaceuticals, Inc. $935,080
- Cardinal Health 414, LLC $607,664
- Cardinal Health 414 LLC $272,717
- Cardinal Health 108, LLC $143.74
- UroMed, Inc. $79.37
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 530
- Transactions 828
About Lymphoseek
Lymphoseek is a drug associated with $1.8M in payments to 530 healthcare providers, recorded across 828 transactions in the CMS Open Payments database. The primary manufacturer is Navidea Biopharmaceuticals, Inc..
Payment data is available from 2017 to 2020. In 2020, $272,717 was paid across 95 transactions to 51 doctors.
The most common payment nature for Lymphoseek is "Unspecified" ($1.3M, 71.4% of total).
Lymphoseek is associated with 12 research studies, including "An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous Injection and Skeletal Joint Imaging with SPECT in Subjects with Active Rheumatoid Arthritis and Healthy Controls" ($233,409).